Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Henninger

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Cutaneous Medicine and Surgery|May 16, 2006
Safe psoriasis control: a new outcome measure for the composite assessment of the efficacy and safety of psoriasis treatmentKim A Papp, Eric Henninger
BMC Dermatology|September 21, 2006
Evaluation of efalizumab using safe psoriasis controlKim A Papp, Eric Henninger
Archives of Dermatological Research|October 6, 2006
The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumabCarlo Pincelli, Eric Henninger, Florence Casset-Semanaz
Lifetime Data Analysis|November 16, 2011
A parametric model fitting time to first event for overdispersed data: application to time to relapse in multiple sclerosisPaola Siri, Eric Henninger, Maria Pia Sormani
BMC Dermatology|December 20, 2005
Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]Jean-Paul Ortonne, Neil Shear, Stephen Shumack, et al.
Expert Opinion on Drug Delivery|June 5, 2023
Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 yearsFrancesco Piras, Lilian Arnaud, Eric Henninger, et al.
Annals of the Rheumatic Diseases|July 31, 2009
Lack of effect of TNFalpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studiesMike J L Peters, Pauline Watt, Lynne Cherry, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Cutaneous Medicine and Surgery|May 16, 2006
Safe psoriasis control: a new outcome measure for the composite assessment of the efficacy and safety of psoriasis treatmentKim A Papp, Eric Henninger
BMC Dermatology|September 21, 2006
Evaluation of efalizumab using safe psoriasis controlKim A Papp, Eric Henninger
Archives of Dermatological Research|October 6, 2006
The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumabCarlo Pincelli, Eric Henninger, Florence Casset-Semanaz
Lifetime Data Analysis|November 16, 2011
A parametric model fitting time to first event for overdispersed data: application to time to relapse in multiple sclerosisPaola Siri, Eric Henninger, Maria Pia Sormani
BMC Dermatology|December 20, 2005
Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]Jean-Paul Ortonne, Neil Shear, Stephen Shumack, et al.
Expert Opinion on Drug Delivery|June 5, 2023
Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 yearsFrancesco Piras, Lilian Arnaud, Eric Henninger, et al.
Annals of the Rheumatic Diseases|July 31, 2009
Lack of effect of TNFalpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studiesMike J L Peters, Pauline Watt, Lynne Cherry, et al.
Pageof 1